Matches in SemOpenAlex for { <https://semopenalex.org/work/W2590128314> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2590128314 abstract "192 Background: Despite recent advances with newer androgen receptor(AR) pathway inhibitors, treatment resistance in castrate resistant prostate cancer continues to remain a clinical problem. Co-targeting approaches are of significant interest to slow the progression of disease and delay the onset of resistance. With both Akt and MEK pathways becoming activated as prostate cancer develops resistance to AR-targeted therapy, this study explores co-targeting these pathways in AR positive prostate cancer models. Methods: Using in vitro models of prostate cancer progression from androgen dependent to castrate resistant and ENZ-resistant disease, we evaluated the effect of Akt and/or MEK inhibition with AZD5363 and PD0325901, respectively, on cell proliferation, apoptosis and downstream signalling pathways. For in vivo models, we tested the combination of Akt and MEK inhibition castrated mice bearing MR49F and 22RV1 cells which are resistant to ENZ. Results: Inhibition of Akt reduced S6 phosphorylation, inhibited growth and induced apoptosis in LNCaP-derived cells; the addition of a MEK inhibitor increased apoptosis and cell cycle arrest, but did not further decrease cell proliferation. In contrast, PTEN wild-type 22RV1 cells demonstrated a greater sensitivity to MEK inhibition, but were generally insensitive to Akt inhibition. In vivo, combination of Akt and MEK inhibition resulted in more consistent tumour growth inhibition of MR49F xenografts and longer disease specific survival than Akt inhibitor monotherapy, with induction of pERK staining being evident in some AZD5363 monotherapy treated tumours. Conversely, 22RV1 xenografts had greater resistance to Akt inhibition and greater sensitivity to MEK inhibition. Conclusions: Our data suggest that combination of Akt and MEK inhibition may improve prostate cancer control in ENZ-resistant prostate cancer. Further, with the major effect in both MR49F and 22RV1 xenografts attributable to one inhibitor, our results also suggest the importance of characterizing the dominant oncogenic pathway in each patient’s tumour in order to select optimal therapy." @default.
- W2590128314 created "2017-03-03" @default.
- W2590128314 creator A5000275517 @default.
- W2590128314 creator A5006602557 @default.
- W2590128314 creator A5010847790 @default.
- W2590128314 creator A5034110828 @default.
- W2590128314 creator A5062125605 @default.
- W2590128314 creator A5081653545 @default.
- W2590128314 date "2016-01-10" @default.
- W2590128314 modified "2023-10-16" @default.
- W2590128314 title "Combined Akt and MEK pathway blockade in pre-clinical models of enzalutamide-resistant prostate cancer." @default.
- W2590128314 doi "https://doi.org/10.1200/jco.2016.34.2_suppl.192" @default.
- W2590128314 hasPublicationYear "2016" @default.
- W2590128314 type Work @default.
- W2590128314 sameAs 2590128314 @default.
- W2590128314 citedByCount "0" @default.
- W2590128314 crossrefType "journal-article" @default.
- W2590128314 hasAuthorship W2590128314A5000275517 @default.
- W2590128314 hasAuthorship W2590128314A5006602557 @default.
- W2590128314 hasAuthorship W2590128314A5010847790 @default.
- W2590128314 hasAuthorship W2590128314A5034110828 @default.
- W2590128314 hasAuthorship W2590128314A5062125605 @default.
- W2590128314 hasAuthorship W2590128314A5081653545 @default.
- W2590128314 hasConcept C121608353 @default.
- W2590128314 hasConcept C126322002 @default.
- W2590128314 hasConcept C190283241 @default.
- W2590128314 hasConcept C2776551883 @default.
- W2590128314 hasConcept C2777609662 @default.
- W2590128314 hasConcept C2779707156 @default.
- W2590128314 hasConcept C2779723316 @default.
- W2590128314 hasConcept C2780192828 @default.
- W2590128314 hasConcept C502942594 @default.
- W2590128314 hasConcept C55493867 @default.
- W2590128314 hasConcept C61367390 @default.
- W2590128314 hasConcept C62112901 @default.
- W2590128314 hasConcept C71924100 @default.
- W2590128314 hasConcept C75217442 @default.
- W2590128314 hasConcept C86554907 @default.
- W2590128314 hasConcept C86803240 @default.
- W2590128314 hasConceptScore W2590128314C121608353 @default.
- W2590128314 hasConceptScore W2590128314C126322002 @default.
- W2590128314 hasConceptScore W2590128314C190283241 @default.
- W2590128314 hasConceptScore W2590128314C2776551883 @default.
- W2590128314 hasConceptScore W2590128314C2777609662 @default.
- W2590128314 hasConceptScore W2590128314C2779707156 @default.
- W2590128314 hasConceptScore W2590128314C2779723316 @default.
- W2590128314 hasConceptScore W2590128314C2780192828 @default.
- W2590128314 hasConceptScore W2590128314C502942594 @default.
- W2590128314 hasConceptScore W2590128314C55493867 @default.
- W2590128314 hasConceptScore W2590128314C61367390 @default.
- W2590128314 hasConceptScore W2590128314C62112901 @default.
- W2590128314 hasConceptScore W2590128314C71924100 @default.
- W2590128314 hasConceptScore W2590128314C75217442 @default.
- W2590128314 hasConceptScore W2590128314C86554907 @default.
- W2590128314 hasConceptScore W2590128314C86803240 @default.
- W2590128314 hasLocation W25901283141 @default.
- W2590128314 hasOpenAccess W2590128314 @default.
- W2590128314 hasPrimaryLocation W25901283141 @default.
- W2590128314 hasRelatedWork W2030981986 @default.
- W2590128314 hasRelatedWork W2442795568 @default.
- W2590128314 hasRelatedWork W2503901337 @default.
- W2590128314 hasRelatedWork W2806156214 @default.
- W2590128314 hasRelatedWork W2889369899 @default.
- W2590128314 hasRelatedWork W3112701574 @default.
- W2590128314 hasRelatedWork W3181847396 @default.
- W2590128314 hasRelatedWork W3198382015 @default.
- W2590128314 hasRelatedWork W4310603203 @default.
- W2590128314 hasRelatedWork W4361849348 @default.
- W2590128314 isParatext "false" @default.
- W2590128314 isRetracted "false" @default.
- W2590128314 magId "2590128314" @default.
- W2590128314 workType "article" @default.